Report
Valens Research

SUPN - Embedded Expectations Analysis - 2019 08 01

Supernus Pharmaceuticals, Inc (SUPN:USA) currently trades below historical averages relative to UAFRS-based (Uniform) Earnings with a 7.4x Uniform P/E, implying bearish expectations for the firm. Moreover, management is concerned about revenue and expense pressures, potential acquisitions, and potential acquisitions.

Valens' qualitative analysis of the firm's Q1 2019 earnings call highlights that management may be concerned about the sustainability of the effectiveness and marketability of their new product SPN-810. Furthermore, they may be concerned about the potential to find quality assets that are worth acquiring.

Additionally, management may be concerned about continued headwinds to revenue due to high deductibility patient healthcare plans, and may be downplaying cost pressures related to SPN-812 going forward.
Underlying
Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company has launched Oxtellar XR and Trokendi XR, its two treatments for epilepsy. In addition, the company has launched Trokendi XR for the prophylaxis of migraine headache in adults and adolescents. The company's product candidates for the treatment of psychiatric disorders include: SPN-810 to treat impulsive aggression in children and adolescents who have attention deficit hyperactivity disorder (ADHD); SPN-812, a non-stimulant candidate to treat patients who have ADHD; SPN-809 for the treatment of depression; and SPN-604 for the treatment of bipolar.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch